What is Engine Biosciences?
Headquartered in Singapore and established in 2014, Engine Biosciences operates at the vanguard of precision medicine. The company utilizes advanced machine learning algorithms to decode complex biological networks, effectively identifying novel therapeutic targets and accelerating the drug development lifecycle. By integrating high-throughput genomics with artificial intelligence, Engine Biosciences addresses the inherent inefficiencies in traditional pharmaceutical research, offering a scalable solution to some of the most challenging diseases in modern medicine. Its market position is bolstered by a robust intellectual property portfolio and a strategic focus on bridging the gap between computational insights and clinical application.
How much funding has Engine Biosciences raised?
Engine Biosciences has raised a total of $88M across 3 funding rounds:
Angel/Seed
$10M
Other Financing Round
$18M
Series A
$60M
Angel/Seed (2018): $10M, investors not publicly disclosed
Other Financing Round (2023): $18M led by Polaris Partners and EDBI
Series A (2023): $60M supported by Vectr Ventures, Dimensions Capital, Goodman Capital, DHVC, WI Harper Group, Invus, WuXi AppTec, Baidu Ventures, EDBI, Polaris Partners, and Nest.Bio
Key Investors in Engine Biosciences
Polaris Partners
A venture capital firm specializing in backing transformational companies in the biotech and healthcare sectors, providing deep operational expertise and resources for long-term growth.
EDBI
A Singapore-based global investor focused on high-growth technology sectors, dedicated to catalyzing industrial transformation and building sustainable legacies through strategic capital.
Vectr Ventures
A global early-stage Venture Studio based in Hong Kong that partners with entrepreneurs to build disruptive products, bridging traditional and modern markets across Asia and beyond.
What's next for Engine Biosciences?
With the successful closure of this major strategic investment, Engine Biosciences is well-positioned to transition into a more aggressive phase of clinical development and platform expansion. The capital will likely be deployed to enhance its proprietary AI engine, expand its internal research capabilities, and potentially forge new collaborative partnerships with global pharmaceutical entities. As the company matures, the focus will shift toward validating its lead candidates in clinical settings, thereby proving the efficacy of its machine learning-led approach in delivering tangible patient outcomes. This trajectory suggests a clear path toward becoming a dominant force in the global biotech ecosystem.
See full Engine Biosciences company page
